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MonolayerClinical pulmonary surfactant is routinely used to treat premature newbornswith respiratory distress syndrome,
and has shown great potential in alleviating a number of neonatal and adult respiratory diseases. Despite
extensive study of chemical composition, surface activity, and clinical performance of various surfactant
preparations, a direct comparison of surfactant ﬁlms is still lacking. In this study, we use atomic forcemicroscopy
to characterize and compare four animal-derived clinical surfactants currently used throughout the world, i.e.,
Survanta, Curosurf, Infasurf and BLES. These modiﬁed-natural surfactants are further compared to dipalmitoyl
phosphatidylcholine (DPPC), a synthetic model surfactant of DPPC:palmitoyl-oleoyl phosphatidylglycerol
(POPG) (7:3), and endogenous bovine natural surfactant. Atomic forcemicroscopy reveals signiﬁcant differences
in the lateral structure and molecular organization of these surfactant preparations. These differences are
discussed in terms of DPPC and cholesterol contents. We conclude that all animal-derived clinical surfactants
assume a similar structure of multilayers of ﬂuid phospholipids closely attached to an interfacial monolayer
enriched in DPPC, at physiologically relevant surface pressures. This study provides the ﬁrst comprehensive
survey of the lateral structure of clinical surfactants at various surface pressures. Itmay have clinical implications
on future application and development of surfactant preparations.302, Honolulu, HI 96822, USA.
ll rights reserved.© 2011 Elsevier B.V. All rights reserved.1. Introduction
The use of clinical pulmonary surfactant began three decades ago
since Fujiwara et al. ﬁrst reported a successful trial of surfactant therapy
in a small groupof premature infantsusing amodiﬁednatural surfactant
extracted from bovine lungs [1]. Since then, surfactant replacement
therapy has become the standard therapeutic intervention to treat
respiratory distress syndrome (RDS) in preterm infants [2]. With its use
over the past three decades, it is estimated that surfactant therapy alone
contributes to a 6% reduction in infantmortality in the United States [3].
A number of clinical surfactant preparations have been developed
worldwide. Based on the surfactant protein content, these preparations
are generally divided into the ﬁrst-generation protein-free synthetic
surfactants, the new generation synthetic surfactants that contain
simpliﬁed peptides or recombinant surfactant protein analogs, and the
modiﬁed natural surfactants derived from animal sources [3–5]. Among
these preparations, protein-free synthetic surfactants have faded away
partly due to their relatively poor biophysical properties but more
because of suboptimal clinical performance; while peptide-containing
synthetic surfactants, although promising, are still under development
[3].Being the only surfactant preparations used in current clinical
practice, animal-derived modiﬁed-natural surfactants have been
extensively studied. Meta-analyses and retrospective reviews on the
comparison between modiﬁed-natural surfactants and synthetic
surfactants [6–10], comparison among different modiﬁed-natural
surfactants [11,12], and comparison of surfactant administration
regimes [13,14], are well documented. Compared to the systematic
study of these surfactant preparations in clinical trials, there are few in
vitro studies that compare their biochemical and biophysical properties
[15–17]. Direct characterization and comparison of surfactant ﬁlms at
the microscale and nanoscale are still lacking.
Application of microscopic and surface spectroscopic techniques to
the studyof pulmonary surfactantshas revolutionizedourunderstanding
of these preparations in the last decade [5,18,19]. Direct ﬁlm imaging
with ﬂuorescencemicroscopy, scanning probemicroscopy, and time-
of-ﬂight secondary ion mass spectrometry (ToF-SIMS) has revealed
phospholipid phase separation, phospholipid–protein interaction, and
localized chemical composition of pulmonary surfactant ﬁlms [5,18,19].
This information signiﬁcantly complements the conventional in vitro
assessment of clinical surfactants, and is especially crucial for mecha-
nistic study.
Among thedifferentbiophysicochemical characterization techniques,
atomic force microscopy (AFM) has been proven to be an ideal imaging
technique and sensitive probing tool for studying pulmonary surfac-
tant ﬁlms [5,18–21]. AFM is superior to conventional ﬂuorescence
microscopy by permitting submicron resolution and eliminating the
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is requisite in electron microscopy. Moreover, AFM can detect not only
two-dimensional but also three-dimensional topographic features
and hence is capable of studying bothmonolayered andmultilayered
surfactant ﬁlms.
In the present study, we report the ﬁrst comprehensive comparison
ofﬁlmstructure forallmajor animal-derivedclinical surfactants currently
used throughout the world, including Survanta (Abbott Laboratories,
North Chicago, IL, USA), Curosurf (Chiesi Farmaceutici, Parma, Italy),
Infasurf (ONY Inc., Amherst, NY, USA), and BLES (BLES Biochemicals,
London, ON, Canada). Survanta and Infasurf are licensed in the USA.
Survanta is also licensed in Japan under the trade name of Surfacten
(Tokyo Tanabe, Tokyo, Japan). Curosurf is licensed in Europe and theUSA
(Cornerstone Therapeutics, Cary, NC, USA). BLES is licensed mainly in
Canada. To gain a better understanding of the surfactant composition–
structure correlation, we also include in the comparison pure dipalmi-
toyl phosphatidylcholine (DPPC), DPPC:palmitoyl-oleoyl phosphatidyl-
glycerol (POPG) (7:3) as a simple protein-free model system, and
endogenous bovine natural surfactant (BNS)without organic extraction
topreserve theactual in vivo surfactant compositions, includingsurfactant
protein A (SP-A).
2. Materials and methods
2.1. Materials
DPPC (16:0/16:0 PC) andPOPG(16:0/18:1PG)were purchased from
Avanti Polar Lipids (Alabaster, AL, USA) and used without further
puriﬁcation. Both DPPC and POPGwere dissolved in chloroform to form
stock solutions at 1 mg/mL. A simple protein-free model surfactant was
prepared bymixingDPPC and POPG at aweight ratio of 7 to 3. In spite of
being a very simple model system, DPPC:POPG (7:3) contains both
zwitterionic (PC) and anionic (PG) headgroups, and both disaturated
(dipalmitoyl) and unsaturated (palmitoyl-oleoyl) acyl chains. It has
been proven to be a simple yet effective model to represent some
biophysical properties of natural surfactants [5].
Bovine natural surfactant (BNS) was obtained from bronchopul-
monary lavage of freshly slaughtered cattle with a saline/magnesium
chloride/calcium chloride solution and isolated by density gradient
centrifugation [22]. Without organic extraction, BNS preserves most
components of the endogenous surfactant, including the hydrophilic
SP-A. The phospholipid concentration of the original stock suspen-
sion was determined to be ~16 mg/mL by the phosphorus assay. BNS
was stored frozen. At the day of experiment it was diluted to 5 mg
phospholipids/mL using a saline buffer of 0.9% NaCl, 1.5 mM CaCl2,
and 2.5 mM HEPES, adjusted to pH 7.0.
Curosurf, Infasurf, and BLES were donated by the pharmaceutical
companies and Survanta was obtained from the Newborn Special Care
Unit at Kapi'olani Medical Center for Women and Children. These
clinical preparations are designated modiﬁed-natural surfactants as
they undergo organic extraction during the manufacture, which
removes the hydrophilic protein (SP-A) and in some cases reduces the
content of hydrophobic proteins (SP-B/C) [15]. Additional procedures
are involved in the manufacture of Survanta, Curosurf and BLES to
remove/reduce neutral lipids, mainly cholesterol. Survanta is further
supplemented with synthetic DPPC, palmitic acid and tripalmitin. The
detailed chemical compositions of these four clinical surfactants have
been well-documented [4,5,15–17,22–24] and summarized in Table 1
together with synthetic surfactants and BNS, in the order of approxi-
mately decreasing DPPC content. It should be noted that these values
are obtained from the manufacturers and from the literature, and
because in some cases different methodologies have been applied,
direct comparison cannot necessarily be made in all cases. All four
clinical surfactants were extracted by chloroform-methanol using
a methodmodiﬁed fromBligh andDyer [25]. The chloroform-methanol
extracts were dried under a nitrogen stream and re-dissolved inchloroform to a ﬁnal concentration of 1 mg/mL. All stock solutionswere
stored at−20 °C until use.
All solvents used were HPLC grade. The water used was Milli-Q
ultrapure water (Millipore, Billerica, MA) which has a resistivity higher
than 18 MΩ-cm at room temperature.
2.2. Methods
2.2.1. Langmuir–Blodgett trough
Spreading, compression and Langmuir–Blodgett (LB) transfer of
surfactant ﬁlms were conductedwith a LB trough (KSVNima, Coventry,
UK) at room temperature (20±1 °C). This trough is equipped with two
Delrin barriers to minimize ﬁlm leakage [26]. The trough contains a
~160 mL subphase and has a large operational surface area of ~300 cm2,
which overcomes the pressure restriction imposed by a smaller trough
[20,21].
2.2.1.1. Film spreading. All ﬁlms were prepared by spreading samples
on ultrapure water. Our previous studies showed that spreading on
buffer instead of pure water caused no detectable differences in the
compression isotherms [20,21]. Films were spread by depositing tiny
droplets of samples uniformly throughout the air–water interface
using a 10 μL microsyringe. Synthetic (DPPC and DPPC:POPG) and
clinical surfactant preparations (Survanta, Curosurf, Infasurf and BLES)
were spread from 1 mg/mL chloroform-extracted solutions, while BNS
was spread from a 5 mg/mL aqueous suspension. Our previous studies
have demonstrated that spreading a clinical surfactant (BLES) from a
chloroform-extracted solution or an aqueous suspension dose not
affect the compression isotherm and ﬁlm structure [20,21]. All initial
spreading increased surface pressure (π) to 1–3 mN/m. The volume
of spread samples varies from 20 to 30 μL for different surfactant
preparations. After spreading, allﬁlmswere left undisturbed for 10 min
to allow equilibrium and evaporation of solvent.
2.2.1.2. Film compression. All spread ﬁlms were compressed at a rate
of 20 cm2/min, namely 0.1% initial surface area per second. During
compression, surface pressure–area (π–A) isotherms were recorded.
The trough surface area (cm2) rather than the absolute molecular
area (Å2/molecule) was used to express the compression isotherms.
This is due to the difﬁculty of controlling the exact amount of surfactant
molecules at the air–water interface (thus the accurate molecular area)
when the ﬁlms were spread from aqueous media (as to BNS) [20,21],
and the difﬁculty of actually estimating the molecular mass of different
clinical surfactant preparations (as to Survanta, Curosurf, Infasurf
and BLES). The use of surface area also facilitates the comparison of
compression isotherms of different surfactant preparations.
2.2.1.3. Film transfer. For atomic force microscopy imaging, surfactant
ﬁlms at the air–water interfacewere transferred to the surface of freshly
cleaved mica using the LB technique. Surfactant ﬁlms at controlled
constant π were deposited onto the mica surface by elevating the
previously submergedmica vertically through the air–water interface at
a rate of 1 mm/min. Deposited ﬁlms were scanned by AFM within
2 hours of deposition. Aging of LB ﬁlms in air over this time period is
considered to have negligible effects on ﬁlm structure [20,21].
2.2.2. Atomic force microscopy (AFM)
Topographical images of LB samples were obtained using an Innova
AFM (Bruker, Santa Barbara, CA). Samples were scanned in air. Each
sample was characterized at multiple locations with various scan areas
to ensure the detection of representative structures. Both contact mode
and tappingmodewere used. The different scanmodes gave equivalent
results. A silicon nitride cantilever with a spring constant of 0.12 N/m
and a nominal tip radius of 2 nmwasused in contactmode, and a silicon
probe with a resonance frequency of 300 kHz and a spring constant
of 40 N/m was used in tapping mode. Scan parameters, such as the
Table 1
Lipid and protein compositions of synthetic, modiﬁed-natural, and natural surfactants used in this study [4,5,15–17,22–24].a
Generic name DPPC DPPC:POPG(7:3) Beractant Poractant alfa Calfactant BLES BNS
Trade name – – SURVANTA® CUROSURF® INFASURF® BLES® –
Source Synthetic Synthetic Bovine lung mince Porcine lung mince Calf lung lavage Bovine lung lavage Bovine lung lavage
Phospholipids 100 100 84 99 91 96 85
PC/DPPC 100/100 70/70 71/50 69/47 79/43 77/41 69/36
PG 0 30 2.4 1.2 4.5 13 10
PE 0 0 3.4 4.5–7.4 2.8 2.6 3.0
PI+PS 0 0 1.3 4.5–8.4 4.0 1.0 2.0
LPC 0 0 1.5 1.0–7.0 b 1.0 0.9 0.2
SM 0 0 3.4 1.8–7.9 0.8 1.4 2.0
Neutral Lipids
Cholesterol 0 0 b 0.2 0 5–8 2–3 5–8
Free fatty acids 0 0 5.8–14 n/a 0.64 n/a 0.25
Hydrophilic Proteins (SP-A) 0 0 0 0 0 0 8.0
Hydrophobic proteins 0 0 0.94 1.1 1.6–2.2 2.0 2.0
SP-B 0 0 0.04 0.4 0.9 0.5 1.0
SP-C 0 0 0.9 0.7 0.7–1.3 1.5 1.0
BLES: Bovine lipid extract surfactant; BNS: bovine natural surfactant; PC: phosphatidylcholine; DPPC: dipalmitoyl phosphatidylcholine; POPG: palmitoyl-oleoyl phosphatidylglycerol;
PG: phosphatidylglycerol; PS: phosphatidylserine; PE: phosphatidylethanol; PI: phosphatidylinositol; LPC: lysophosphatidylcholine; SM: Sphingomyelin; SP: surfactant protein.
a Data shown in this table represent weight percentage of each composition with respect to the total mass of pulmonary surfactant.
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scan rate, were optimized in such a way that the lowest force and
highest gains possiblewere used to scan the sample [27]. Analysis of the
AFM images, such as determination of relative height of the surface
topography, was carried out by Nanoscope software (ver. 7.30). ImageJ
(National Institutes of Health, Bethesda, MD) was used to quantify area
fractions of condensed domains.70
80
Region IV2.2.3. Statistics
For each surfactant, LB sample preparation was repeated for at
least 3 times at each surface pressure. Multiple AFM images were
taken for each sample at each surface pressure. All data are expressed
as mean±SD (nN5 unless otherwise indicated). Group differences
were analyzed by one-way ANOVA using OriginPro8.0. A Pb0.05 was
considered statistically signiﬁcant.0 50 100 150 200 250 300
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Fig. 1. Comparison of typical compression isotherms of various synthetic, modiﬁed-
natural, and natural surfactant ﬁlms at room temperature. The two protein-free
synthetic systems are pure DPPC and DPPC:POPG (7:3). The four clinical modiﬁed-
natural surfactants are Survanta, Curosurf, Infasurf, and BLES. The native natural
surfactant for comparison is bovine natural surfactant (BNS). All pulmonary surfactants
were spread as monolayers to an initial surface pressure (π) of 1–3 mN/m prior to
compression. Surfactant ﬁlms were compressed at an identical rate of 20 cm2/min until
ﬁlm collapse. Four pressure-dependent regions are detected for the compression
isotherms of protein-containing modiﬁed and natural surfactants. These are: Region I.
Monolayer region at π≤40 mN/m; Region II. Monolayer-to-multilayer transition region
at 40bπb50 mN/m; Region III. Multilayer region at π≥50 mN/m; and Region IV.
Collapse region at 72 mN/m for all ﬁlms but Survanta, which collapses at 62 mN/m. The
structural nature of these four regions is revealed in Fig. 2 by AFM.3. Results
3.1. Comparison of compression isotherms
Fig. 1 compares the typical compression isotherms of DPPC, DPPC:
POPG (7:3), Survanta, Curosurf, Infasurf, BLES, and BNS. First, compres-
sion isotherms of all modiﬁed-natural surfactants and BNS feature a
plateau region at π 40–50 mN/m. In contrast to these protein-containing
surfactants, pure DPPC shows a well-characterized isotherm with a
phase transition plateau at 3–5 mN/m [28,29], and DPPC:POPG
shows no apparent plateau region. Due to the existence of the plateau,
compression isotherms of modiﬁed-natural and natural surfactants can
be separated into four regions, as indicated in Fig. 1. In the regions before
and after reaching the plateau, surfactant ﬁlms have a signiﬁcantly
lower ﬁlm compressibility (i.e., less area reduction to increase π) than
the plateau region. The fourth region refers to the ﬁlm collapse plateau
at which the surfactant ﬁlms reach their maximum π. The molecular
natureof these four regions is discussedbelow in combinationwithAFM
observations. Second, the compression isotherms shift, after passing
the plateau region, from right to left in the order of DPPC, DPPC:POPG,
Survanta, Curosurf, Infasurf, BLES, and BNS. This order in general
agrees with the rank of decreasing DPPC content in each preparation
(see Table 1). Third, all surfactant ﬁlms but Survanta collapse at π of
~72 mN/m, corresponding to near-zero surface tension at room
temperature. Survanta, on the other hand, collapses at ~62 mN/m.3.2. Comparison of ﬁlm structures
Fig. 2 is a compilation of AFM images comparingmicro- and nano-
structures of different surfactant ﬁlms obtained at increasing π. All
surfactants, with the exception of DPPC, were studied at 20, 30, 40,
50, 60 mN/m, and the pressure at which the ﬁlms collapse. In
comparison, DPPC was studied at 2.8, 4.0, 10, 30, 60 and 72 mN/m.
These characteristic pressures were selected to cover the complete
Fig. 2. Comparison of characteristic AFM topographic images of various synthetic, modiﬁed-natural, and natural surfactant ﬁlms at increasing surface pressure (π). All surfactants but
DPPC were studied at a series of π of 20, 30, 40, 50, 60 mN/m, and the π at which the ﬁlm collapses, i.e., 72 mN/m for DPPC:POPG, Curosurf, Infasurf, BLES, and BNS, and 62 mN/m for
Survanta. In comparison, DPPC was studied at π of 2.8, 4.0, 10, 30, 60 and 72 mN/m. These characteristic pressures were selected to cover the complete and detailed evolution of each
surfactant ﬁlm under compression, i.e., before, during and after the plateau region in the compression isotherm (Fig. 1). All AFM images were obtained with the same scan
parameters, i.e., Setpoint=1 V; PID Gains=3/2/0; and Scan rate=1 Hz. The AFM scan area was 50×50 μm for all images. For the purpose of comparison among different
surfactants, the full z-range was set to be 5 nm for all images at π≤40 mN/m, and 20 nm for πN40 mN/m (with the only exception being DPPC at 60 mN/m, the z-range was reduced
to 5 nm to demonstrate topographic features). Relative height of critical structures is pointed by arrows. Critical lateral structures indicated by rectangular boxes are shown in high-
resolution images in Fig. 3.
1835H. Zhang et al. / Biochimica et Biophysica Acta 1808 (2011) 1832–1842and detailed evolution of each surfactant ﬁlm under compression.
For the purpose of comparison, all AFM images were obtained with
the same scan parameters, i.e., Setpoint=1 V; PID Gains=3/2/0;
and Scan rate=1 Hz. All images have the same scan area of 50×50 μm.
The full z-range is 5 nm for all images at π≤40 mN/m (i.e., before
reaching the plateau), and 20 nm for all images at πN40 mN/m (i.e.,
after passing the plateau). The only exception is the DPPC image at
60 mN/m, which has a full z-range of 5 nm to demonstrate shallow
features.
Fig. 3 shows selectedheight proﬁles, three-dimensional surfaceplots,
and high-resolution AFM images, corresponding to regions indicated by
boxes in Fig. 2. These images have different scan areas and z-ranges,
adjusted for optimum presentation of detailed ﬁlm structures.
3.2.1. DPPC
As shown in the ﬁrst column of Fig. 2, pure DPPC remains a
monolayer up to collapse at 72 mN/m. At a very low pressure of
2.8 mN/m, the DPPC monolayer is in a ﬂuid-like liquid-expanded (LE)
phase in which the phospholipid molecules have a low packing
density and the fatty acid chains remain largely disordered and ﬂuid
[28,29]. At 4.0 mN/m, the DPPC monolayer shows well-deﬁned chiral
microdomains and small nanodomains [5,28–31]. The domain forma-
tion indicates coexistence of the LE phase with a more ordered andrigid tilted-condensed (TC) phase, which extends ~1 nm beyond the
LE phase [5,21,32]. Note that when discussing phospholipid phase
behavior we adopt the nomenclature proposed by Kaganer et al. [32],
who suggest the use of TC phase to replace the commonly used liquid-
condensed (LC) phase. The line tracing in Fig. 3A illustrates heights of
microdomains and nanodomains, relative to the continuous LE phase.
Both microdomains and nanodomains have the same height, indicat-
ing they are both in the TC phase [29–31]. The plateau shown in the
DPPC isotherm at 3–5 mN/m therefore indicates a ﬁrst-order phase
transition [28,32]. After passing the phase transition plateau, the DPPC
monolayer at 10 and 30 mN/m is primarily in a homogenous TC phase,
thus with a very low ﬁlm compressibility. When pressure is increased
to 60 mN/m, a number of small “peaks” of only 0.4 nm high (indicated
by the arrow) appear uniformly in the monolayer, indicating onset of
monolayer destabilization under the extreme lateral compression. At
72 mN/m, the DPPC monolayer collapses completely, as indicated by
the formation of a ﬁlm collapse plateau in the isotherm and bilayer
stacks (Fig. 3B) on top of the monolayer.
3.2.2. DPPC:POPG (7:3)
The second column of Fig. 2 shows the ﬁlm structure of the protein-
free binary model system DPPC:POPG (7:3). At 20 mN/m, the DPPC:
POPG monolayer shows phospholipid phase separation. Lateral
1836 H. Zhang et al. / Biochimica et Biophysica Acta 1808 (2011) 1832–1842chemical analysis in previous ToF-SIMS experiments proved that the TC
domains consist of DPPC and the surrounding LE phase contains less
ordered POPG [33–35]. In addition to the circular domains, there are
stripes with the same height as the TC domains and organized in the
direction perpendicular to the dippingdirection. Similar phenomenon isalso found for Curosurf. It appears that these stripes are not due to an
AFM tip artifact as they remain unchanged as varying scan direction,
rate, and force, or using different scanmodes. These might be due to an
artifact of LB transfer inwhich substrate-mediated condensation occurs
during or after the transfer [36]. However, the reason why this artifact
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Fig. 4. Quantiﬁcation results of monolayer coverage of tilted-condensed (TC) domains
upon ﬁlm compression. Monolayers of DPPC:POPG (7:3), Survanta, Curosurf, Infasurf,
BLES, and BNS were quantiﬁed at surface pressures (π) of 20, 30, and 40 mN/m. At each
pressure, area fractions of microdomains, nanodomains, and total TC domains (sum of
micro- and nano-domains) were quantiﬁed with image analysis. *Pb0.05 for
differences between area fractions of microdomains at 30 and 40 mN/m, for Infasurf,
BLES, and BNS.
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unknown.
With pressure increase to 30 mN/m, the TC domains grow in size. At
40 mN/m, the TC domains become less detectable in the topographic
image. A closer look at the ﬁlm (Fig. 3C) conﬁrms that the TC domains
are packed together to form a somewhat continuous phasewith “holes”
of ~0.5 nm in depth, likely due to the trapped LE phase. It appears that
further increasing pressure to 50 mN/m induces formation of isolated
bilayer structures (~3 nminheight, aspointed by thearrow) attached to
the interfacial monolayer, due to localized ﬁlm collapse. The multilayer
structures grow in the lateral dimension but not signiﬁcantly in height
(~4 nm as pointed) with further increasing pressure to 60 mN/m. The
ﬁlm eventually collapses at 72 mN/m,where patterns of ﬁlm folding are
clearly observed along the direction of ﬁlm compression (Fig. 3D).
3.2.3. Survanta
Survanta is prepared fromminced bovine lung tissue, extractedwith
chloroform-methanol, and further puriﬁed by precipitation with ethyl
acetate. These puriﬁcation procedures result in a loss of cholesterol
and a reduction in SP-B [15,17]. Due to its relatively poor capacity in
reducing surface tension, Survanta is further supplemented with
synthetic DPPC, palmitic acid and tripalmitin. As shown in the third
column of Fig. 2, Survanta monolayers at 20 mN/m present a clear
TC-LE phase separation, indicated by formation of round-shaped TC
domains mainly in the micrometer size. The area coverage of the
TC phase increases continuously with increasing pressure up to
40 mN/m (Fig. 4). At 50 mN/m, i.e., immediately past the plateau in
the compression isotherm, the original monolayer is transformed
into multilayers. A surface plot at 50 mN/m (Fig. 3E) demonstrates
that a matrix of multilayers (about two bilayers high relative to the
surface monolayer) is formed surrounding the TC domains in the
interfacial monolayer. Similar structure of Survanta has been reported
by another group [37]. This ﬁlm structure strongly implies that the
multilayersmust be initiated from the LEphase in theoriginal surfactant
monolayers. As π is increased to 60 mN/m, themultilayersmainly grow
in the lateral dimension but not in the altitudinal direction (Fig. 3F);
while the TCdomains in the interfacialmonolayer are further packed. At
62 mN/m, the Survanta ﬁlm permanently collapses and forms localized
folding structures in arbitrary orientations, which differs from the
whole-ﬁlm, orientational folding of DPPC:POPG ﬁlm at its collapse
pressure.
3.2.4. Curosurf
Curosurf is prepared fromminced porcine lung tissue. It is depleted
of cholesterol by undergoing gel-chromatography to remove all neutral
lipids during manufacture [4]. As shown in the fourth column of Fig. 2,
the Curosurf monolayer at 20 mN/m exhibits signiﬁcantly fewer, but
larger, noncircular domains, compared to Survanta, presumably
indicating a higher ﬁlm viscosity [38,39]. With increasing π, the domain
shape becomes more ramiﬁed. Nanodomains with the same height of
microdomains tend to line up horizontally to form stripes (Fig. 3G). As
pressure is increased to 50 mN/m, the Curosurf ﬁlm displays moderateFig. 3. High-resolution AFM images, as indicated by rectangular boxes in Fig. 2, demonstrati
height proﬁle shows the surface topography along the line tracing indicated in the AFM imag
and worm-like nanodomains, both ~1 nm higher than the surrounding liquid-expended (L
stacks ejected from the interfacial monolayer at the collapse pressure. C. Monolayer of DPPC:
phase with “holes” of LE phase ~0.5 nm lower. D. Surface plot (three-dimensional topogra
folding along the direction of lateral compression. E. Surface plot of Survanta ﬁlm at 50 mN/m
from the surrounding LE phase. F. Survanta ﬁlm at 60 mN/m, illustrating an increasing multi
signiﬁcantly, compared to 50 mN/m. G. Curosurf monolayer at 40 mN/m shows a single mic
height proﬁle. H. Curosurf ﬁlm at 50 mN/m, showing a single TCmicrodomain with moderate
monolayer at 20 mN/m shows the cholesterol-mediated liquid-ordered (LO) phase and a
phospholipid phase. The lipid chain order of the LO phase is intermediate between the TC
height). J. Infasurf monolayer at 40 mN/m, demonstrating a single TC-in-LO domain with an i
30 mN/m). K. BLES monolayer at 40 mN/m, showing clearly a decrease of microdomains i
microdomains traced out by multilayers formed from the surrounding LE phase. M. BNS mo
spots, likely SP-A aggregates squeezed out of the monolayer at this pressure. N. BNS ﬁlm at(only ~1.5 nmhigh) buckling along the direction of lateral compression
(Fig. 3H). At 60 mN/m and even 72 mN/m where the ﬁlm ultimately
collapses, the multilayer structures only grow slightly to ~4 nm high,
indicating very limited ﬁlm collapse and high ﬁlm stability.
3.2.5. Infasurf
Infasurf is prepared from lung lavage of newborn calves by
centrifugation and organic solvent extraction, and it contains all of
the hydrophobic components of natural surfactant. Compared to
Survanta and Curosurf, Infasurf has a high cholesterol content
(Table 1). It is well known that cholesterol has a profound inﬂuence
on the phase behavior of phospholipid monolayers and membranes
[5,40–43]. Depending on its ratio to phospholipids in monolayers,
cholesterol can selectively partition into TC phase phospholipid
domains and induce a new liquid-ordered (LO) phase, whose degree
of lipid chain order is intermediate between the LE and TC phases
[5,40–43]. As shown in the ﬁfth column of Fig. 2, all three phases
(i.e., LE, LO, and TC) are detected in the Infasurf monolayer. As a
consequence of partitioning into the TC domains, the high cholesterol
content in Infasurf results in a unique domain-in-domain (TC-in-LO)
structure. In Fig. 3I, scanning from left to right, one observes the
background LEphase, amicroscale TCdomain 0.8 nmhigher than the LE
phase, a LO phase 0.2 nm lower than the TC phase, and nanoscale TC
domains 0.8 nm higher than the surrounding LE phase. These height
variations are in good agreement with the relative chain order of these
three phases.ng detailed structural features of surfactant ﬁlms. A. DPPC monolayer at 4.0 mN/m. The
e. It shows that the tilted-condensed (TC) phase consists of both leaf-like microdomains
E) phase. B. Collapsed DPPC monolayer at 72 mN/m, showing the formation of bilayer
POPG (7:3) at 40 mN/m, showing that the condensed domains merge into a continuous
phic image) of DPPC:POPG ﬁlm at the collapse pressure (i.e., 72 mN/m), showing ﬁlm
. It shows that the TC microdomains are traced out by higher multilayers that originate
layer density in the lateral dimension while the height of multilayers does not increase
rodomain with lines of nanodomains, as indicated by the intensive ﬂuctuations in the
ﬁlm buckling, indicated by vertical lines of collapse sites of only ~1.5 nm high. I. Infasurf
unique TC-in-LO structure as a consequence of cholesterol partitioning into the TC
and LE phases, as indicated by height differences detected by AFM (i.e., TCNLONLE in
ncreasing number of nanodomains and evident shrink of the TC core (2.5 μm vs. 5 μm at
n size and increase of nanodomains in number. L. BLES ﬁlm at 50 mN/m, showing TC
nolayer at 40 mN/m, showing the detailed morphology of nanodomains and some high
50 mN/m, showing detailed multilayer structure.
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of theTC-in-LOphase)ﬁrst increase in size aspressure increases from20
to 30 mN/m, and then decrease in size as pressure increases from 30 to
40 mN/m. Fig. 3J is a high resolution image that demonstrates evident
shrinkage of the TCmicrodomains at 40 mN/m.With further increasing
pressure to 50 mN/m, the Infasurf monolayer is transformed into
multilayers (~6 nm higher than the surface monolayer). Similar to
Survanta, themultilayers clearly encompass the TCmicrodomains in the
interfacial monolayer, which indicates that the multilayers stem from
the LE (and possibly also the LO) phase in the original monolayer. Upon
increasing pressure to 60 mN/m, the multilayers are closely packed in
the lateral dimension but do not signiﬁcantly increase in height. At
72 mN/m, a few isolated protrusions of ~10 nmhigh appear. Since AFM
measures relative height, these protrusions are 10 nm higher than the
tightly packed multilayers in the background. This collapse mechanism
is quite different from the folding mechanism of the model system,
Survanta and Curosurf.
3.2.6. BLES
BLES is prepared from adult cows being slaughtered for food with
a foaming procedure, followed by organic solvent extraction [22].
BLES is similar to Infasurf in phospholipid and protein proﬁles (Table 1).
However, BLES has a reduced cholesterol content as it undergoes an
acetone extraction. Under the current manufacturing process, the ﬁnal
cholesterol content in BLES is 2–3% [44], i.e., one-third to one-half
of that in bovine natural surfactant. As shown in the sixth column of
Fig. 2, BLES ﬁlms generally consist of LE and TC phases, due to the
reduced cholesterol content (note that few domain-in-domain struc-
tures appear only at 20 mN/m). Similar to Infasurf, the TCmicrodomains
in BLESﬁrst increase frompressures of 20 to 30 mN/m, and then decrease
from 30 to 40 mN/m. Associated with the decrease of microdomains
is a signiﬁcant increase in the number of nanodomains (Fig. 3K). This
pressure-dependent domain conversion is in good agreement with
our previous study of BLES [21]. It is also clear that the multilayers
at 50 mN/m originate from the LE phase and encompass the TC
microdomains (Fig. 3L). Topographical analysis shows that the multi-
layered protrusions consist of stacked bilayers of 5–6 nm high. The
formation of multilayers at 50 mN/m is also consistent with previous
AFM studies using BLES and model surfactants [21,41,45–52]. Never-
theless, themultilayered protrusionsdetected in thepresent study seem
to be smaller than those found previously with BLES [21,46,51,52]. This
might be due to batch-to-batch variations of animal-derived prepara-
tions. With further increasing pressure, the multilayers pack tightly and
ﬁnally collapse at 72 mN/m as individual protrusions (~12 nm), similar
to the collapse mechanism of Infasurf.
3.2.7. Bovine natural surfactant
The last column of Fig. 2 shows the structure of bovine natural
surfactant (BNS), which contains the full spectrum of surfactant
phospholipids, 5–8% cholesterol, and both hydrophobic (SP-B/C) and
hydrophilic (SP-A) proteins (Table 1).Different frombothmodel system
and modiﬁed-natural surfactants used in clinical practice, the domain
size in BNS is primarily in the nanometer range. Especially at 40 mN/m,
only nanodomains appear at themonolayer. Somehigh spots,measured
to be ~4 nm in height, appear at 40 mN/m (Fig. 3M). These high spots
are likely to be SP-A aggregates squeezed out of the monolayer at this
pressure [21]. All these observations are in good agreement with our
previous work of recombinant BLES with 5% SP-A [21]. Multilayer
structures of ~6 nm in height appear at 50 mN/m (Fig. 3N) and are
packed closely at 60 mN/m.At72 mN/m,BNS shows signiﬁcantlyhigher
collapse protrusions (~32 nm) compared to Infasurf and BLES.
3.3. Quantitative analysis of condensed domains
Fig. 4 shows quantiﬁcation results for the condensed phospholipid
domains (i.e., the TC phase) in micrometer-size (microdomains) andnanometer-size (nanodomains) for all surfactantmonolayers, excluding
DPPC. The quantiﬁcation is limited to monolayers, i.e., at π≤40 mN/m.
At higher pressures, the formation of multilayers prevents accurate
quantiﬁcation of domain areas, especially nanodomains, at the
interfacial monolayer.
As shown in Fig. 4, the total area fraction of condensed domains
(combinedmicrodomainsandnanodomains) increases for all surfactant
preparations with increasing pressure from 20 to 40 mN/m. The total
area fraction of condensed domains at 40 mN/m is approximately equal
to the fraction of disaturated phospholipids (mainly DPPC) in each
surfactant preparation (Table 1). In contrast to the monotonic increase
of total condensed domains, the pressure-dependence ofmicrodomains
and nanodomains varies between different surfactant preparations. For
DPPC:POPG and Survanta, the microdomains are predominant, espe-
cially at 40 mN/m, i.e., the onset of monolayer-to-multilayer transition.
In contrast, in the monolayers of Curosurf, Infasurf, BLES, and BNS,
nanodomains represent the major fraction of condensed phase at
40 mN/m. Importantly, there is a signiﬁcant decrease (Pb0.05) of area
fraction of microdomains and increase of nanodomains upon pressure
increase from 30 to 40 mN/m, in Infasurf, BLES and BNS, i.e., the three
surfactant preparations that contain cholesterol.
4. Discussion
Langmuir monolayers self-assembled at the air–water interface
are an established in vitro model of studying biophysical properties
of pulmonary surfactant [5,19,41,53–55]. Film imaging with AFM
obtains direct topographical features of these surfactant ﬁlms. Interpre-
tationof the ﬁlm topography in terms of lateral structure andmolecular
organization is based on well-established experimental evidence
obtained from molecular characterization techniques, such as ﬂuores-
cence microscopy and ToF-SIMS [5,18–21,33–35].
It is found that although all clinical surfactants exhibit similar
ﬁlm compressibility, they show very different lateral structure and
molecular organization (Figs. 2 and 3). These differences are largely
due to the different biochemical compositions of animal-derived
preparations, which are consequences of varied animal sources
(bovine vs. porcine) and production procedures (bronchopulmon-
ary lavage vs. lung mincing) [4]. As shown in Table 1, clinical
surfactant preparations differ in phospholipids, cholesterol, individ-
ual surfactant proteins (SP-B and SP-C), and additives (such as free
fatty acids). Here, we limit our discussion on only two surfactant
components, DPPC and cholesterol. However, it should be noted that
the exclusion of surfactant proteins from the discussion is not to
deemphasize their effects. It is well known that SP-B and SP-C play a
crucial role in monolayer-to-multilayer transition upon ﬁlm com-
pression, adsorption and readsorption/respreading of surfactant
ﬁlm upon ﬁlm expansion [5,41,49,56–58]. Recent mechanistic
studies have shown that although at a small content (b2 wt.%),
these two hydrophobic proteins may function collaboratively or
independently and most likely in synergy with cholesterol in
optimizing the biophysical properties of pulmonary surfactant
[59–61].
According to their compression isotherms, we have identiﬁed four
π-dependent regions for all protein-containing modiﬁed and natural
surfactants. As noted in Fig. 1, these four regions, based on ﬁlm
structures revealed by AFM, are referred to as I, monolayer region; II,
monolayer-to-multilayer transition region; III, multilayer region; and
IV, collapse region.
4.1. Region I. Phospholipid phase separation in surfactant monolayers
At π lower than ~40 mN/m,modiﬁed and natural surfactants are in
monolayers. Surfactant monolayers in this region are conceivably of
no signiﬁcant physiological relevance as surface tension in the lungs
during normal tidal breathing most likely varies from near-zero to not
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70 mN/m [62]. However, surfactant monolayer in this region may be
germane to certain abnormal and disease conditions marked with
elevated alveolar surface tension due to surfactant deﬁciency and/or
dysfunction [63].
First, we found that at the onset of monolayer-to-multilayer
transition (i.e., 40 mN/m), the total area fractions of condensed
domains for all surfactant preparations are approximately equal to
themolecular fraction of disaturated phospholipids (mainly DPPC) in
each individual surfactant. This observation suggests that 1) there is
no alteration of chemical composition of monolayers within Region I,
and 2) regardless of their speciﬁc contents, DPPC molecules in all
surfactant preparations are fully packed into a rigid and ordered TC
phase up to 40 mN/m.
Second, we found that cholesterol plays an important role in
regulating the phospholipid phase behavior in surfactant mono-
layers. With 5–8% in weight or 10–16% in mole, cholesterol induces a
new phase in Infasurf monolayers, indicated by the appearance of a
unique domain-in-domain structure. A similar structure has been
reported in BLES supplemented with extra cholesterol [64] and in rat
surfactant that contains ~8 wt.% cholesterol [44]. Our topographic
analysis indicates this domain-in-domain structure to be a TC-in-LO
phase. This composition–structure interpretation is also supported by
previous evidence of this structure disappearing after cholesterol
extraction and reappearing with cholesterol supplementation [44,64].
The concept of cholesterol-mediated LO phase in surfactantmonolayers
is extended from the study of cholesterol-containing bilayers [5,41].
Ipsen et al. proposed that cholesterol intercalates in lipid bilayers to
regulate lipid chain order [65]. Consequently, the ﬂuidity and other
biophysical properties of the resultant liquid-ordered (Lo) phase in
bilayers are intermediate between the liquid-disordered (Ld) phase (i.e.,
the bilayer counterpart of the LE phase) and the solid-ordered (So)
phase (i.e., the bilayer counterpart of the TC phase) [42,43,65]. It should
also be noted that the cholesterol concentration in Infasurf falls into the
range of So–Lo phase coexistence at sub-melting temperature, as
indicated by the generic binary phase diagram [42,43,65]. Therefore,
the formation of LO phase in Infasurf monolayers is not completely
unexpected.
In addition, we demonstrated dissolution of TC microdomains at
40 mN/m in all cholesterol-containing surfactants (Infasurf, BLES,
BNS) but not in cholesterol-free surfactants (DPPC:POPG, Survanta,
and Curosurf). This phenomenon was previously referred to as phase
remixing, a process attributed to cholesterol [66]. Our recent study
with BLES suggested that the dissolution of TC microdomains was at
the expense of increasing nanodomains [21], which is also conﬁrmed
in this studywith Infasurf and BNS. Interestingly, high-resolution AFM
reveals that phase remixing may be regulated by the cholesterol-
mediated LO phase in the monolayer, which facilitates dissolution of
TCmicrodomains into nanodomains upon increasing π (Figs. 3I vs. 3J),
presumably by reducing line tension at the domain boundaries
[21,66]. The dissociation of TC microdomains into nanodomains
signiﬁcantly enhances the uniformity of phase coexistence at the
interfacial monolayer, thus promoting the subsequent squeeze-out of
ﬂuid phospholipids into multilayered protrusions upon further
compression in Region II.
4.2. Region II. Monolayer-to-multilayer transition at the equilibrium
spreading pressure
At π between ~40 and ~50 mN/m, modiﬁed and natural surfac-
tants are in a transition state from amonolayer to amultilayer. Surface
pressure in this range, or ~45 mN/m representatively, is the equilibrium
spreading pressure (πe) of ﬂuid phospholipids, at which fully-hydrated
phospholipid vesicles reach equilibrium with the phospholipid mono-
layer at the air–water interface [5]. The πe is also the maximum π
that can be reached by fully-hydrated phospholipid vesicles duringadsorption or spreading. Further increasing π, if possible, can be only
achieved by lateral ﬁlm compression. Molecular structure in this region
could represent the surfactant ﬁlm formed by de novo adsorption of
endogenous surfactant, orbyspreadingof exogenous clinical surfactants.
Our studyprovides direct experimental evidence ofﬁlm reﬁning due
to selective squeeze-out of the ﬂuid components at this pressure range.
First, we have shown that compression isotherms of different modiﬁed
and natural surfactants in this region shift to the left in the order of
decreasing DPPC content. As a result, a longer plateau or more area
reduction is required to reﬁne amonolayer containing a higher amount
of non-DPPC components. Second, AFMreveals a squeeze-out process in
monolayers of Survanta, Infasurf and BLES. It is shown that multilayers
at 50 mN/m originate from the LE phase and encompass the TC
microdomains in the interfacialmonolayer. These AFMobservations are
supported by recent chemical characterization of BLES using ToF-SIMS,
which revealed that the lower domains consist of disaturated
phospholipids (mainly DPPC) and the surrounding higher phase is
enriched in unsaturated phospholipids [19]. Selective squeeze-out of
ﬂuid components (those with lower πe) from multicomponent
phospholipid monolayers is a well studied physicochemical phenom-
enon [67]. The squeeze-out process inmonolayers of protein-containing
surfactants was found to be reversible [5,67]. In this way, the squeezed
out multilayers form a surface-associated surfactant reservoir for
effective ﬁlm replenishment during expansion.
Curosurf has the highest amount of phospholipids and lowest
amount of neutral lipids in all clinical surfactant preparations.
Different from the others, monolayers of Curosurf in this pressure
range display only moderate ﬁlm buckling along the direction of
lateral compression. This may be related to the nonuniform phase
coexistence at its interfacial monolayer. With a signiﬁcantly large
domain size and lack of cholesterol-mediated microdomain-to-
nanodomain conversation, monolayers of Curosurf intrinsically lack
nucleation sites for the reversible collapse, usually occurring at the
domain boundaries [67,68].
4.3. Region III. Metastable monolayer with attached multilayers
At π above πe but before reaching the ultimate ﬁlm collapse,
surfactant ﬁlms are in a metastable state with an interfacial monolayer
attached with squeezed out multilayers. This region covers a π range
from ~50 to 72 mN/m, most likely representing the physiologically
relevant π range. It should be noted that although surfactant ﬁlms in
this region are in a multilayer structure, surface activity must still be
controlled by the interfacial monolayer. The fact that all natural
surfactant ﬁlms show very low compressibility similar to that of
DPPC monolayers in this region indicates the interfacial monolayers
must be enriched with DPPC in the TC phase. Importantly, with
increasing π to 60 mN/m, we found that multilayer structures increase
density in the lateral dimension but do not signiﬁcantly grow in
height. This observation indicates that the ﬁlm reﬁning process (i.e.,
selective squeeze-out) is largely completed during the plateau region.
With further compression, the interfacialmonolayer already enriched in
DPPC (as well as the attachedmultilayers) is further packed to decrease
surface tension to near-zero. How pulmonary surfactant ﬁlms reach
low surface tension has remained an open question [5,54,55]. Our
present data provide direct experimental evidence in support of a
detailed biophysical mechanism of combined phospholipid phase
separation and multilayer formation due to squeeze-out of ﬂuid
phospholipid components.
4.4. Region IV. Collapse mechanisms of surfactant ﬁlms
Collapse pressure (πc) is the maximum π that can be reached and
sustained by a phospholipid ﬁlm under lateral compression. At πc,
surfactant ﬁlms irreversibly collapse by excluding phospholipid vesicles
of the same composition as the interfacial monolayers. This process is
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ﬂuid components from the interfacial monolayer at πe. In mammal
lungs, ultimate ﬁlm collapse at πc, if any, may only be limited and
transient at end-expiration as this process is not energetically favorable.
We found that all surfactant ﬁlms but Survanta collapse at π ~72 mN/m,
corresponding to a near-zero surface tension. The early collapse of
Survanta ﬁlms has been well-documented [15–17]. Compared to other
clinical preparations, Survanta lacks SP-B (Table 1). However, mono-
layers of synthetic model surfactant (DPPC:POPG) without surfactant
proteins collapse at 72 mN/m. Hence, the early collapse of Survanta
ﬁlms might be due to the supplemented palmitic acid components
because monolayers of palmitic acid collapse on a pure water subphase
at only ~50 mN/m [69].
We found that cholesterol also plays a role in regulating the
collapse mechanism of surfactant ﬁlms. Surfactant ﬁlms without
cholesterol (DPPC:POPG, Survanta, and Curosurf) appear to collapse
with a folding mechanism, like an elastic sheet. In contrast, surfactant
ﬁlms with cholesterol (Infasurf, BLES, and BNS) appear to collapse
with a protrusion mechanism, in which multilayered protrusions are
uniformly nucleated throughout the entire ﬁlm. The cholesterol-
regulated ﬁlm collapse mechanism may be best explained by fusion
pore formation [19] and/or variations in ﬁlm ﬂuidity [70], as also
suggested by molecular dynamics simulations [71,72].
4.5. Clinical implications
Deﬁciency and/or dysfunction of pulmonary surfactant are involved
in many airway, parenchymal, and interstitial lung diseases [63]. In
addition to its success in treating RDS, surfactant therapy in recent years
has been applied to a variety of neonatal, pediatric, and adult respiratory
conditions [2,3,73], such as the chronic lung disease (also known as
bronchopulmonary dysplasia) [74], asthma [75,76], meconium aspira-
tion syndrome [77], neonatal pulmonary hypertension, congenital
pneumonia, congenital diaphragmatic hernia, pulmonary hemorrhage
[2,3,73], acute lung injury and acute respiratory distress syndrome [78].
Althoughmore studies are needed to establish the efﬁcacy of surfactant
therapy for many of these conditions, clinical surfactants appear to be a
promising and versatile therapeutic intervention [2,3,73,74]. It should
be noted that new applications for clinical surfactants are still emerging
[79,80], including their use as a carrier to deliver corticosteroids directly
to the lungs of premature newbornswith or at high risk for chronic lung
disease [81]. Therefore, it is of vital importance to characterize and
compare exogenous surfactant preparations currently available for
clinical practice, both biochemically and biophysically. In vitro charac-
terization of composition–structure correlation of surfactant ﬁlms can
also provide implications for the development of new generation
synthetic designer surfactants.
To date, no synthetic surfactant available can confer a comparable
biophysical and clinical performance as the animal-derived prepara-
tions [3–5]. Two new generation synthetic surfactants that contain a
simple peptide or protein analogs, Surfaxin and Venticute, both rely
on DPPC:POPG (~7:3) as the lipid skeleton [3–5]. DPPC is the only
major phospholipid component in pulmonary surfactant with a
bilayer transition temperature above the core body temperature [5].
Therefore, it has long been considered to be the main surface active
component in pulmonary surfactant. However, recent comparative
biology studies suggested that the DPPC content is highly variable
among mammals and it is even not the major phospholipid in some
species [24,82]. The DPPC content also varies signiﬁcantly in different
animal-derived clinical surfactants, from ~40% in BLES to ~50% in
Survanta (Table 1). In spite of this variation in DPPC content, clinical
superiority in terms of statistical differences in mortality or days in
neonatal intensive care units related to difference surfactant prepa-
rations has not been established [3–5].
Our AFM observations found that regardless of the DPPC content of a
particular surfactant preparation, all clinical surfactant ﬁlms assume asimilar molecular organization at the physiologically relevant surface
tension range, i.e., multilayers of ﬂuid phospholipids closely attached to
an interfacial monolayer enriched in DPPC. This ﬁlm structure results
froma reﬁningprocess aroundπe, atwhichsurfactantﬁlmsare formed in
vivoeither by adsorptionof theendogenous surfactantor by spreadingof
the exogenous surfactant.
Our data therefore suggest that a high content of DPPC may not
necessarily be crucial for designing a synthetic surfactant. Actually, a
high DPPC content may compromise the biophysical properties,
especially adsorption, of a surfactant substitution. This view is in line
with that of Holm et al. who showed that increasing DPPC content to
60% or 80% in a model system did not increase dynamic surface
activity but compromised adsorption [83]. This may also explain the
limited success of synthetic surfactants enriched with DPPC, such as
Exosurf and ALEC. In view of balancing surface tension lowering
ability and rapid adsorption, it might be desirable to design a
functional synthetic surfactant with the lowest possible DPPC content.
The threshold DPPC content is still to be determined, but it appears
that 40% DPPC as in bovine natural surfactant is sufﬁcient to maintain
adequate biophysical properties with the aid of hydrophobic
surfactant proteins.
Being a minor lipid component with limited analysis in the past,
the role of cholesterol in pulmonary surfactant has attracted
signiﬁcant attention in recent years [40,44,46,64,84]. Our data suggest
that a cholesterol content as low as 2–3% (as in BLES) can induce
signiﬁcant variation in surfactant ﬁlms, including formation of
cholesterol-mediated phospholipid phases, variation of ﬁlm ﬂuidity
and collapsemechanism. Although cholesterol at a supraphysiological
level exhibits signiﬁcant inhibition on surfactant function, cholesterol
at the physiological level or lower appears not to affect the surface
tension lowering ability [46,50,64,84,85]. Therefore, cholesterol-free
surfactant preparations might be more efﬁcacious for treating
certain conditions such as ARDS, in which an elevated level of
cholesterol is found in the bronchoalveolar lavage ﬂuid of these
patients [86,87].5. Conclusions
We report the ﬁrst comprehensive characterization and compar-
ison of micro- and nano-structures of all major animal-derived clinical
surfactant preparations using AFM. This comparative study reveals
the composition–structure correlation of clinical surfactants as well as
the biophysical mechanisms of pulmonary surfactant ﬁlms in
response to lateral compression. This study may have implications
for clinical applications of surfactant preparations and translational
value for the development of new generation synthetic designer
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